Journal: Microbes and Infection

Article Title: Management of COVID-19: current status and future prospects

doi: 10.1016/j.micinf.2021.104832

Figure Lengend Snippet: Vaccines candidates that are currently on/completed Phase III human trials. (Updated on April 02, 2021) [ 92 , 149 , 150 ].

Article Snippet: Covaxin , Bharat Biotech International Limited, Iqvia Pty Ltd, Indian Council of Medical Research, , NCT04641481 , 2 , 80.6% , India, Iran, Mauritius, Nepal, Zimbabwe..

Techniques: Vaccines, Plasmid Preparation, Control, Recombinant

Journal: The Lancet. Healthy Longevity

Article Title: COVID-19 vaccines in older adults with cancer: a Young International Society of Geriatric Oncology perspective

doi: 10.1016/S2666-7568(21)00060-X

Figure Lengend Snippet: Available vaccines and priority groups in various countries as of March 1, 2021

Article Snippet: India , Covaxin, Covishield (AstraZeneca/Serum Institute of India) , January, 2021 , Health-care workers; frontline workers (police, prison staff, municipal workers); people aged ≥50 years and people aged <50 years with comorbidities (including cancer) , Prioritised only among people aged <50 years.

Techniques: Vaccines

Journal: Vaccines

Article Title: Comparison of Biological, Pharmacological Characteristics, Indications, Contraindications, Efficacy, and Adverse Effects of Inactivated Whole-Virus COVID-19 Vaccines Sinopharm, CoronaVac, and Covaxin: An Observational Study

doi: 10.3390/vaccines11040826

Figure Lengend Snippet: Efficacy of Sinopharm, CoronaVac, and Covaxin COVID-19 vaccines in the prevention of COVID-19 cases and hospital admission.

Article Snippet: The FDA has provided emergency authorization for the administration of the Sinopharm, CoronaVac, and Covaxin COVID-19 vaccines.

Techniques: Vaccines, Variant Assay, Infection, Control

Journal: Applied Soft Computing

Article Title: Generalized Susceptible–Exposed–Infectious–Recovered model and its contributing factors for analysing the death and recovery rates of the COVID-19 pandemic

doi: 10.1016/j.asoc.2022.108973

Figure Lengend Snippet: Countries in this study with their respective vaccination period and vaccine used.

Article Snippet: India , 16 / 1 / 21 − 28 / 2 / 21 , Covaxin, Oxford/AstraZeneca.

Techniques:

Journal: Applied Soft Computing

Article Title: Generalized Susceptible–Exposed–Infectious–Recovered model and its contributing factors for analysing the death and recovery rates of the COVID-19 pandemic

doi: 10.1016/j.asoc.2022.108973

Figure Lengend Snippet: Vaccine used in countries in this study with its respective efficacy.

Article Snippet: India , 16 / 1 / 21 − 28 / 2 / 21 , Covaxin, Oxford/AstraZeneca.

Techniques: